Quantcast

Latest drug discovery Stories

2014-07-23 16:26:42

LONDON, July 23, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Partial Seizure Global Clinical Trials Review, H2, 2014https://www.reportbuyer.com/product/2243634/Partial-Seizure-Global-Clinical-Trials-Review-H2-2014.htmlPartial Seizure Global Clinical Trials Review, H2, 2014SummaryGlobalData's clinical trial report, "Partial Seizure Global Clinical Trials Review, H2, 2014" provides data on the Partial Seizure clinical trial scenario. This report provides...

2014-07-23 12:32:31

LONDON, July 23, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Generalized Seizures Global Clinical Trials Review, H2, 2014https://www.reportbuyer.com/product/2243626/Generalized-Seizures-Global-Clinical-Trials-Review-H2-2014.htmlGeneralized Seizures Global Clinical Trials Review, H2, 2014SummaryGlobalData's clinical trial report, "Generalized Seizures Global Clinical Trials Review, H2, 2014" provides data on the Generalized Seizures clinical trial...

2014-07-17 08:28:41

SANTA ROSA, Calif., July 17, 2014 /PRNewswire/ -- Ruthigen, Inc., (NASDAQ: RTGN) today announced that it has treated the first human subjects with its leading drug candidate RUT58-60 in a 30 patient, 21-day skin irritation trial, which is expected to be completed in August 2014. In June 2014, Ruthigen's Investigational New Drug (IND) application became effective following review by the U.S. Food and Drug Administration (FDA). Ruthigen is developing RUT58-60 as a safe and fast...

2014-07-16 08:28:30

DCVax®-Direct Phase II Trial Preparations and Manufacturing Expansion Underway BETHESDA, Md., July 16, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Phase I portion of the Company's Phase I/II DCVax-Direct clinical trial has completed its 36-patient target recruitment, and the Company is now underway with preparations for the Phase II...

2014-07-15 10:12:40

The Institute for Genomic Biology Antibiotic resistance is depleting our arsenal against deadly diseases and infections, such as tuberculosis and Staph infections, but recent research shows promise to speed up the drug discovery process. In a study reported in ACS Chemical Biology, University of Illinois researchers developed a new technique to quickly uncover novel, medically relevant products produced by bacteria. Past techniques involved screening more than 10,000 samples to find...

2014-07-15 08:28:36

EXTON, Pa., July 15, 2014 /PRNewswire/ -- Absorption Systems, a leader in novel test systems for drug transporters, announces a license agreement with Pfizer Inc., in which Pfizer will in-license Absorption Systems' BCRP-MDCK cells. This cell line is stably transfected with the human ABCG2 gene, which codes for a protein known as BCRP (breast cancer resistance protein). This proprietary human BCRP assay system is designed to enable the testing of new drug candidates for interactions...

2014-07-14 23:06:34

Market Size - $1,121.9 million in 2013; Market Growth - CAGR of 21.1%; Market Trends – Growth in the research initiatives for genome sequencing and proteomic analysis of biological systems for new drug discovery - new report by Grand View Research. View full report - http://www.grandviewresearch.com/industry-analysis/computational-biology-market. San Francisco, California (PRWEB) July 14, 2014 The global market for computational biology is expected to reach USD 4,285.1 million by 2020...

2014-07-14 12:27:06

Researchers to Use IBM Blue Gene/Q Supercomputer for Computational Drug Design and Discovery RESEARCH TRIANGLE PARK, N.C., July 14, 2014 /PRNewswire/ -- Cloud Pharmaceuticals, Inc., a therapeutics company focused on cloud-based drug design and development, announced today the expansion of its drug design and development program. The company has been granted supercomputing time at Argonne National Laboratory to design inhibitors of multiple parasitic targets. Through a...

2014-07-10 10:28:40

Boston Children's Hospital Study calls for more focus on long-term outcomes in pediatric trials of drugs intended for chronic use Over the last 60 years, the U.S. Food and Drug Administration (FDA) approved 20 medications for attention deficit/hyperactivity disorder (ADHD) based on clinical trials that were not designed to study their long-term efficacy and safety or to detect rare adverse events, researchers at Boston Children's Hospital report today in PLOS ONE. The study highlights...

2014-07-10 04:21:33

SHANGHAI, July 10, 2014 /PRNewswire/ -- HD Biosciences Co., Ltd. (HDB), the Marshall Institute for Interdisciplinary Research (MIIR) and the Marshall University Joan C. Edwards School of Medicine announced the new partnership to co-develop potential anti-cancer drugs. Under the agreement, the partners will share the costs and risks of discovery and development of new drugs. They will also jointly own intellectual property and commercialization rights of the products developed through...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related